|
Viropro focuses on process development and cGMP manufacturing services. We have an international client base, from small and medium sized companies that are seeking assistance to get their new drug into clinical trials to large Pharma groups interested in biosimilars/biobetters or diversifying into novel biotech drugs. Through our proprietary technologies and flexible business model, Viropro can offer cost-effective and timely solutions to the Biophrama industry from drug concept through to product manufacturing. Financial Statements are now available on the Investors page
Management’s comments: March 21, 2012
Several stockholders have indicated that they would appreciate more regular updates and PRs. Management agrees with the principle and will always disclose publicly all material information either through PRs or 8-K Statements. Quarterly financials including Management’s Discussion and Analysis have been issued frequently as of late through the filings of 10-Qs; last update therefore goes back to February 16, 2012 and it detailed subsequent events till the time of filing. Management will use a very conservative approach to news and update dissemination. To this end, a communication plan will be implemented as soon as return to full disclosure is attained. Management’s comments do not replace or substitute for press releases and they cannot be interpreted as expressing the views and comments of the Board of Directors.
Monday, February 13, 2012 Viropro's first comments on the FDA's Guidance for Industry on Biosimilars Development
Last Thursday, the FDA published draft guidance documents on scientific and quality considerations for companies developing biosimilar products. Viropro’s senior management is pleased with the draft guidance. We feel the Agency has adopted a balanced approach to biosimilar development that will serve the best interest of patients and payers alike. The emphasis placed on strong analytical data and product characterization will bring healthy competition to the current products that have or will soon lose patent protection. Furthermore, the requirements outlined in the FDA’s draft guidance documents correspond with Viropro’s technical strengths. We see this as a step forward for our ongoing and planned biosimilars projects. The clarity brought by these publications should facilitate Viropro's continued development of strong partnerships that will give greater options and more affordable life saving drugs to patients.
Monday, February 8, 2012 In light of yesterday’s trading in the shares of the Company, Management would like to comment on the current state of operations: - Return to full disclosure status remains a priority and to this effect, management expects to file before the end of the current month the 10-Q form for Quarter 2 and 3 of 2011. These are the only two remaining forms to be filed to resume full disclosure status. - Company is still involved with Spectrum Pharmaceuticals as per the Press Release of January 2011 however, as per the agreement, it cannot disclose any information to public for the time being. - Company is still focused on implementing its award winning business plan and a public announcement updating the investment community will be produced shortly. Management is not aware of a particular event that produced yesterday’s trading activity.
Click here for Gilford Securities' report on Viropro Inc. Click here for Viropro’s Fact Sheet Click here for our List of Services
|
 |
|
 | ||
 |
|
|